Heron Therapeutics Inc vs Energy Select Sector SPDR Fund — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Energy Select Sector SPDR Fund trades at $60.91. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | XLE | |
|---|---|---|
Market Cap | $61.47M | — |
Sector | Health | — |
52-Week High | $1.49 | $62.57 |
52-Week Low | $0.32 | $42.33 |
Enterprise Value | $168.21M | — |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
XLE trades at $60.47, up 0.47% with a bullish technical signal from moving averages. The ETF has rallied 40.52% over the past year, driven by strong oil prices and geopolitical tensions in the Middle East. Recent earnings from major holdings like ExxonMobil and Chevron showed profit surges, supporting the sector's momentum. Technical indicators show support at $59 and resistance at $61, with RSI readings in neutral territory suggesting room for further movement.
Outlook remains positive but faces geopolitical risks. The energy sector benefits from elevated oil prices and strong earnings, though concentration in a few large stocks and sensitivity to Middle East tensions present volatility. Analyst sentiment is mixed with some calling the entry point less attractive after the rally, while others see continued upside potential from supply disruptions and AI infrastructure demand.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →